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The aim of this study was to examine the relationship between cadmium (Cd) and 
bladder cancer (urothelial carcinoma of the bladder). Cadmium concentrations in 
two 36-sample series of bladder cancer tissue and blood, from patients with the 
neoplasm, were matched with those of the control group. The amount of heavy 
metal in every tissue sample was determined using atomic absorption spectrometry. 
This was correlated with tumour stage. While the median cadmium concentration 
levels reached statistically lower values in the bladder cancer tissue, as compared 
with the non-cancer one (11.695 ng/g and 56.32 ng/g respectively, p < 0.001), 
the median Cd levels in the blood of the patients with this carcinoma showed no 
statistical difference when compared to those of the control group (8.237 mg/l and 
7.556 mg/l respectively, p = 0.121). The median levels of cadmium in the bladder 
tissue, depending on the stage of the tumour, compared with the tissue without 
the neoplasm, observed the same relationship for both non-muscle invasive and 
muscle-invasive tumours (p < 0.002 and p < 0.02 respectively). This study has 
shown that patients with urothelial carcinoma of the bladder had lower tissue cad-
mium levels than people without tumour while no difference in the Cd blood levels 
between the two groups of patients under investigation was found.
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Introduction
Bladder cancer is the fourth most common cancer 
in men and the ninth most common malignancy in 
women. It accounts for 3.0% of all cancer deaths in 
the male population and 1.5% of all cancer deaths in 
females [1].
Epidemiological and experimental data indicate 
a significant connection between chemical com-
pounds and serious disorders as well as the develop-
ment and progression of several cancers including 
urinary tract tumours [2-9]. Many chemicals, in-
cluding heavy metals and trace elements, have been 
shown to be carcinogens for bladder cancer [10-12]. 
Experimental studies have demonstrated that cadmi-
um can induce both benign and malignant tumour 
formation at various sites including the urinary tract 
[13-16]. Similarly, two epidemiological analyses of 
people exposed to Cd have reported possible asso-
ciations between cadmium and bladder urothelial 
carcinoma [17, 18]. Additionally, higher Cd levels 
in the urine of patients with this tumour have been 
reported, further suggesting its contribution to car-
cinogenesis [19]. Thus far, however, there has been 
no demonstrable direct evidence for the association 
of cadmium with human urothelial carcinoma of the 
bladder.
In our study, we measured the concentration of 
cadmium in the tissue of the bladder tumour and 
compared this to the content in non-cancerous tissue. 
In addition, the concentration of Cd in the blood of 
patients with bladder tumours was compared to con-
trol samples from the patients with non-neoplasm or 
heavy metals-related diseases of the urinary system. 
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Finally, we evaluated the resultant levels depending 
on the stage of the tumour.
Material and methods
This study was approved by the Medical Ethics 
Committee for Human Studies of the Medical Uni-
versity in Bialystok, Poland, and all the procedures 
were carried out in accordance with the Helsinki Dec-
laration of 1975, as revised in 1983. The study was 
conducted on 36 patients with histologically proven 
urothelial carcinoma of the bladder, without lymph 
node involvement or distant metastases. The patients 
included 30 men aged between 41 and 88 (on average 
68.5 years old) and 6 women aged between 52 and 
78 (on average 67 years old). Non-muscle invasive 
cancers (Tis – Ta – T1) occurred in 22 cases and mus-
cle-invasive tumours (T2 – T3 – T4) in 14 patients. 
The grade of histological malignancy G1, G2 and G3 
was found, respectively, in 10, 13, and 10 patients, 
whereas it was not possible to establish with certain-
ty the actual grade of malignancy in 3 patients. Five 
patients had primary non-muscle invasive bladder 
cancer, whereas recurrent urothelial carcinoma of the 
bladder was diagnosed in 31 individuals (17 people 
with non-muscle invasive bladder cancer with disease 
duration of between 6 months and 4 years, and 14 
cases with muscle invasive bladder cancer with pri-
mary non-muscle invasive bladder tumour diagnosed 
between 6 months and 2 years earlier). All individu-
als had normal renal and liver function tests and ab-
dominal ultrasound did not reveal any abnormalities. 
Blood tests and urinalysis were within the normal 
range limits. None of our patients had renal, pancre-
atic or lung malignancy. Moreover, none of the men 
under investigation had testicular or prostate cancer.
The tumours were removed by transurethral re-
section (TURBT) in 29 patients and by cystectomy 
in 7 patients. Just after the bladder or the tumour 
itself had been removed, samples of 1 g of cancer tis-
sue were taken and stored after being snap frozen in 
liquid nitrogen. Before bladder or tumour removal, 
three-millilitre samples of venous blood were collect-
ed from the basilic vein using Vacutainer vacuum sets.
The control material consisted of 15 one-gram 
samples of bladder tissue taken from sex- and age-
matched individuals, who had died from trauma 
(n = 15). Samples were taken during autopsy from 12 
male cadavers aged 54-77 (on average 64 years old) 
and 3 females aged 57-76 (on average 65.5 years old).
Next, 15 three-millilitre samples of venous blood 
from the corresponding sex-and-age-matched pa-
tients, who were in fasting states with non-neoplasm 
or heavy metal-related diseases of the urinary sys-
tem (1 woman with benign pelvic-ureteric junction 
obstruction, 3 with stress incontinence, 3 men with 
scrotal injury, 3 with renal injury, 2 with benign ure-
thral stricture and 3 with hydrocele), were collect-
ed in Vacutainer vacuum sets and used in the con-
trol group. There were 11 samples taken from male 
patients aged 43-86 (on average 67 years old), and 
4 from females aged 52-78 (on average 67.5 years 
old). There was no difference in socioeconomic status 
between the cases and controls. Neither group had 
occupational exposure to cadmium.
Before analysis, the samples were mineralized in 
concentrated nitric acid (V) in a UniClever closed 
microwave system manufactured by Plazmatroni-
ka. The mineralization products were quantitatively 
transferred into polypropylene scintillation vessels. 
Cadmium was quantitatively determined in the 
blood samples that had undergone deproteinisation 
with 1 mol/l nitric acid (V) and 1% Triton X-100 
added as a surface-active agent. The levels of inves-
tigated heavy metal concentration were analysed by 
the atomic absorption spectrometry technique with 
Zeeman background correction on a Hitachi Z-5000 
spectrometer. The Cd content was calculated using 
readings on a standardization curve, formed by re-
cording differences in absorbance and element con-
centration. Cadmium standard solution (1000 mg/l) 
traceable to SRM from NIST in 0.5 mol/l HNO3 
(Merck, Germany) was used to prepare working 
solutions for the calibration curve. The accuracy of 
the cadmium determination method was verified 
using the following certified standard materials: Se-
ronorm 404108 for the whole blood and BCR-184 
for bovine muscle. Accuracy (i.e. % of error) and 
coefficient of variation were calculated for the cer-
tified standards under investigation. The accuracy 
and precision coefficient of variation was 1.9% and 
3.65% for Seronorm 404108 and 0.76% and 3.72% 
for BCR-184, respectively. The detection limit was 
0.053 µg/l. The samples were evaluated in the De-
partment of Bromatology of the Medical University 
of Bialystok, which is involved in a program of in-
tra-laboratory comparative analyses of elements or-
ganized by the Institute of Nuclear Chemistry and 
Technology, and the National Institute of Public 
Health.
Since data in the studied group were not distribut-
ed in a Gaussian manner, the Mann-Whitney U test 
was used. A p value of < 0.05 was considered statisti-
cally significant. The Statistical Package for the Social 
Sciences (SPSS) was used for all statistical analyses.
Results
Median values of cadmium, determined in the 
bladder cancer tissue and blood of the patients with 
urothelial carcinoma of the bladder and the control 
group, are shown in Table I. Figures 1, 2 present Cd 
bladder tissue and blood concentration distribution 
of patients with bladder cancer and controls.
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The median value of cadmium concentration in 
the bladder cancer tissue and in the non-cancer one 
was 11.695 ng/g and 56.32 ng/g, respectively. The 
difference in Cd concentration in the tissues was sta-
tistically significant (p < 0.001). There was no sig-
nificant difference in the blood Cd levels between 
the groups (8.237 µg/l and 7.556 µg/l, respective-
ly, p = 0.121). There was no statistical difference in 
the median value (quartile 1; quartile 3) of cadmium 
concentration in the bladder cancer tissue and in the 
non-cancer one found in men and women, when ana-
lysed by sex [12.3 ng/g (5.7; 46.7) vs. 14.1 ng/g (0.1; 
20.6), p = 0.103, and 56.3 ng/g (51.6; 74.4) vs. 59.0 
ng/g (51.0; 69.6), p = 0.997, respectively]. Similarly, 
no statistical difference in the blood Cd concentration 
between men and women with and without bladder 
cancer was observed [8.0 µg/l (7.1; 9.9) vs. 8.6 µg/l 
(6.5; 16.2), p = 0.756, and 7.4 µg/l (5.8; 8.3) vs. 7.9 
µg/l (5.2; 8.7), p = 0.734, respectively).
Moreover, tissue and blood cadmium levels 
were calculated for the two tumour stage groups 
(one with non-muscle invasive and the other with 
muscle invasive cancers). When processed by the 
non-parametric Mann-Whitney U test, the results 
showed that the median levels of Cd in the bladder 
tissue, depending on the stage of the tumour, were 
significantly lower for both non-muscle invasive 
and muscle-invasive tumours, as compared with 
the tissue without the neoplasm (p < 0.002 and 
p < 0.02 respectively). There was no marked dif-
ference in the cadmium blood levels between peo-
ple with urothelial carcinoma of the bladder and 
the controls, when analysed by the two tumour 
stage groups (see Table II).
Table I. Bladder tissue and blood cadmium concentrations in patients with bladder cancer versus controls
Group n Q1 median Q3 p
Cd blood, mg/l bladder cancer cases 36 7.102 8.237 10.215 0.121
controls 15 5.640 7.556 8.388
Cd bladder tissue, 
ng/g
bladder cancer cases 36 4.858 11.695 36.350 0.001*
controls 15 51.610 56.320 71.990
Cd – cadmium, n – number of samples, Q1 – lower quartile, Q3 – upper quartile; *statistically significant
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Fig. 1. Cadmium (Cd) bladder tissue concentration distri-
bution of patients with bladder cancer and control group
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Fig. 2. Cadmium (Cd) blood concentration distribution of 
patients with bladder cancer and control group
Table II. Bladder tissue and blood cadmium concentrations in patients with non-muscle-invasive vs. muscle-invasive 
bladder cancer
Group n Q1 median Q3 p 
(vs. Control)
Cd blood, mg/l Tis + Ta + T1 22 7.107 8.457 10.512 0.112
T2 + T3 + T4 14 6.994 7.816 9.567 0.553
Cd bladder tissue, ng/g Tis + Ta + T1 22 3.930 10.610 23.913 0.002*
T2 + T3 + T4 14 5.073 12.495 49.478 0.02*
*statistically significant, n – number of samples, Q1 – lower quartile, Q3 – upper quartile
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Discussion
In this study we observed lower tissue cadmium 
levels in the patients with urothelial carcinoma of the 
bladder and no difference in the Cd blood levels be-
tween the two groups of patients under investigation.
Two published case-control studies have suggested 
an association between exposure to cadmium and the 
risk of urinary bladder cancer, as tumours were more 
frequently observed in people who had occupational 
exposure to Cd [17, 18]. These observations could 
theoretically be related to the fact that the urinary 
system is involved in the cadmium removal process 
out of the human organism [20]. Thus, whenever 
this element is present in urine, it may directly act on 
the urothelium, especially inside the bladder, which 
functions as a temporary reservoir for urine and as 
such is exposed to cadmium action for a longer time. 
The above theory has been supported by a study that 
showed increased Cd levels in the urine of people with 
bladder cancer as compared with healthy individuals 
[19]. Moreover, higher cadmium blood levels in men 
with urothelial bladder cancer have been observed in 
one study [21]. Furthermore, an experimental study 
demonstrated that cadmium is able to malignantly 
transform human urothelial cells [22]. Additional-
ly, it has been shown that tumour heterotransplants 
produced by the urothelial cell line UROtsa malig-
nantly transformed by Cd had epithelial features con-
sistent with those of the typical urothelial carcinoma 
of the bladder [23]. Moreover, one study observed 
Kindlin-2 expression (a class of focal adhesion pro-
teins implicated in integrin activation) in urothelium 
of archival human bladder cancer specimens and no 
such expression in normal urothelium [24].
The mechanisms involved in cadmium-induced 
carcinogenesis are, however, unclear. They likely in-
clude free radical-mediated genetic damage, inhibi-
tion of DNA repair, and stimulation of cell prolifera-
tion or apoptosis [15, 25, 26].
Our study does not support the above epidemi-
ological data. We can only speculate why our find-
ings do not validate previous studies. To date, evi-
dence for a link between Cd and bladder cancer was 
found only in two case-control studies of people with 
bladder tumour who had occupational exposure to 
cadmium compounds [17, 18]. One of those studies 
reported only a weak association between the heavy 
metal and tumour, whereas the other found a signif-
icant increase in urothelial carcinoma of the bladder 
in men and women who had high exposure to Cd. 
Epidemiological studies, however, do not prove cau-
sality. Moreover, these types of studies, in particular 
case-control or retrospective ones, are often associat-
ed with serious selection bias [27]. 
One study has shown increased cadmium levels in 
the urine of subjects with bladder cancer, as compared 
with healthy individuals [19]. However, this study 
could be underpowered as the sample size was small 
(6 of 10 patients with bladder cancer had elevated 
urine Cd levels). Of added interest is the evidence 
suggesting that urinary cadmium levels increase with 
age, which is also an important risk factor for bladder 
cancer [28].
One study found significantly higher cadmium 
blood levels in people with bladder cancer than in 
controls [21]. This report, however, was limited to 
men. Moreover, patients with bladder cancer were 
significantly older than those without malignant dis-
ease. Both male gender and age have been identified 
as risk factors for urothelial carcinoma of the bladder 
[29].
It is also possible that neoplastic bladder tissue for 
some unclear reason does not accumulate cadmium. 
This would explain the statistically lower levels of Cd 
which we observed in the bladder tissue of people 
with urothelial carcinoma compared to those in men 
and women without the tumour. However, in such 
cases we would expect lower levels of the heavy met-
al in patients with muscle-invasive tumours than in 
subjects with non-muscle-invasive cancers.
In our study we found no difference in the cadmi-
um blood levels between the two groups of patients 
under investigation. This is an important observa-
tion, as blood Cd reflects current exposure rather 
than whole-body burdens, whereas urinary cadmium 
reflects total burden [20]. On the other hand, Cd 
accumulated in the body influences the blood cad-
mium concentration as it does not decrease to the 
pre-exposure levels after exposure ceases. Thus, Cd 
in blood may serve as a good estimate of the accu-
mulated body burden of heavy metal [30]. There-
fore, the absence of difference in cadmium blood 
levels between subjects with bladder cancer and 
controls provides indirect evidence that both groups 
of people had similar exposure to Cd. North-East-
ern Poland is regarded as un-unpolluted region 
and has been found to have low concentrations of 
Cd in soil [31]. This is mainly due to a lack of an-
thropogenic sources of heavy metals such as indus-
trial waste, mining or smelting activity. Automobile 
exhausts, municipal effluents and smoking are the 
major sources of cadmium in this area. As none of 
our subjects including controls had occupational 
exposure to Cd, no acute increase in blood cadmi-
um levels among patients with bladder cancer and 
controls was observed. It has to be noted, however, 
that a very high tissue cadmium level (168.37 ng/g) 
was found in one patient with bladder cancer. This 
67-year-old man also has a high blood Cd concentra-
tion (48.88 µg/l). Although he had no occupational 
exposure to cadmium, he was living for more than 
25 years in the lower Silesian region of Poland prior 
to moving to the North-Eastern part of the country. 
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The lower Silesian region has been known for a high 
concentration of cadmium in soil [32].
In summary, this study showed that patients with 
urothelial carcinoma of the bladder had lower tissue 
cadmium levels than people without tumour while 
no difference in the Cd blood levels between the two 
groups of patients under investigation was found. 
Further studies are required to assess the biological 
significance of these parameters. Moreover, large ep-
idemiological prospective studies, collecting infor-
mation on occupational, residual and environmental 
exposure to cadmium compounds and their possible 
association with bladder cancer, are needed.
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